52
Participants
Start Date
August 31, 2017
Primary Completion Date
December 20, 2018
Study Completion Date
February 22, 2019
Varlitinib
300mg, oral tablets, twice daily for 2 weeks. Number of cycles: until disease progression, unacceptable toxicity, withdrawal of consent, or death.
mFOLFOX6
concurrent oxaliplatin 85 mg/m2 and leucovorin 400 mg/m2 IV in 500 ml 5% dextrose water (D5W) over 120 minutes on Day 1; then 5 Fluorouracil bolus 400 mg/m2 IV on Day 1 followed by continuous infusion 2400 mg/ m2 over 46 hours starting on Day 1) every 2 weeks. Number of cycles: until disease progression, unacceptable toxicity, withdrawal of consent, or death.
Placebo
oral tablets, twice daily for 2 weeks. Number of cycles: until disease progression, unacceptable toxicity, withdrawal of consent, or death.
mFOLFOX6
concurrent oxaliplatin 85 mg/m2 and leucovorin 400 mg/m2 IV in 500 ml 5% dextrose water (D5W) over 120 minutes on Day 1; then 5 Fluorouracil bolus 400 mg/m2 IV on Day 1 followed by continuous infusion 2400 mg/ m2 over 46 hours starting on Day 1) every 2 weeks. Number of cycles: until disease progression, unacceptable toxicity, withdrawal of consent, or death.
2 Sites, Tallinn
1 Site, Hong Kong
2 Sites, Kaunas
1 Site, Vilnius
2 Sites, Kuala Lumpur
1 Site, Singapore
2 Sites, Daegu
1 Site, Incheon
1 Site, Jeongnam
11 Sites, Seoul
2 Sites, Suwon
1 Site, Kaohsiung City
1 Site, Taichung
1 Site, Taipei
1 Site, Khon Kaen
1 Site, Pathum Thani
Lead Sponsor
ASLAN Pharmaceuticals
OTHER